Authors: Ong, SYK Clarke, SJ Bishop, J Dodds, HM Rivory, LP

Citation: Syk. Ong et al., Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction, ANTI-CANC D, 12(7), 2001, pp. 619-625

Authors: Dodds, HM Rivory, LP

Citation: Hm. Dodds et Lp. Rivory, Comment on a published paper, BR J PHARM, 134(2), 2001, pp. 448-449

Authors: Dodds, HM Clarke, SJ Findlay, M Bishop, JF Robert, J Rivory, LP

Citation: Hm. Dodds et al., Clinical pharmacokinetics of the irinotecan metabolite 4-piperidinopiperidine and its possible clinical importance, CANC CHEMOT, 45(1), 2000, pp. 9-14

Authors: Dodds, HM Bishop, JF Rivory, LP

Citation: Hm. Dodds et al., More about: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin, J NAT CANC, 91(1), 1999, pp. 91-92

Authors: Dodds, HM Rivory, LP

Citation: Hm. Dodds et Lp. Rivory, The mechanism for the inhibition of acetylcholinesterases by irinotecan (CPT-11), MOLEC PHARM, 56(6), 1999, pp. 1346-1353